Article about Canadian guidelines on proton pump inhibitors was misleadingBMJ 2000; 320 doi: http://dx.doi.org/10.1136/bmj.320.7242.1143 (Published 22 April 2000) Cite this as: BMJ 2000;320:1143
- Sheila Frame, vice president, corporate affairs ([email protected])
- AstraZeneca Canada, Mississauga, Ontario, Canada L4Y 1M4
EDITOR—I am writing because AstraZeneca Canada objects to the fact that the BMJ did not ask the company for comment before publishing Shuchman's news article on guidelines about the prescription of proton pump inhibitors in Canada.1 The article misleads readers on several counts.
Firstly, Shuchman writes of a letter that AstraZeneca sent to Dr Anne Holbrook; the letter was sent two years ago to Dr Holbrook as the chair of a government committee. The government of Ontario responded …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial